Rituximab‐ PECC induction followed by 90 Y‐ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT : results from a phase II HOVON study

Pieternella J. Lugtenburg*, Josee M. Zijlstra, Jeanette K. Doorduijn, Lara H. Bohmer, Mels Hoogendoorn, Henriette W. Berenschot, Aart Beeker, Nicole C. van der Burg-de Graauw, Harry C. Schouten, Yavuz M. Bilgin, Marie-Jose Kersten, Harry R. Koene, Alexandra H. E. Herbers, Daphne de Jong, Nathalie Hijmering, King H. Lam, Dana Chitu, Rolf E. Brouwer, Gustaaf W. van Imhoff, Dutch HOVON Group

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) after, or ineligible for, autologous stem cell transplantation (ASCT) have a dismal prognosis. This phase II study evaluated treatment with R-PECC (rituximab, prednisolone, etoposide, chlorambucil, lomustine), every 28 days for 4 cycles in 62 patients, followed by radio-immunotherapy consolidation with Y-90-ibritumomab tiuxetan in responsive patients. Primary endpoints were failure-free survival (FFS) and incidence of grade >= 3 adverse events from start of Y-90-ibritumomab tiuxetan. The overall response rate after R-PECC was 50%. Twenty-nine of 31 responsive patients proceeded to Y-90-ibritumomab tiuxetan. Five out of 15 partial remission patients converted to complete remission after Y-90-ibritumomab tiuxetan. One-year FFS and overall survival (OS) from start of Y-90-ibritumomab tiuxetan was 52% (95% confidence interval [CI], 33-68%) and 62% (95% CI, 42-77%), respectively. One-year FFS and OS from start of R-PECC was 28% (95% CI, 17-39%) and 49% (95% CI, 36-61%), respectively. Toxicities of R-PECC and Y-90-ibritumomab tiuxetan were mainly haematological. In conclusion, for relapsed DLBCL patients the largely oral R-PECC regimen achieves promising response rates, combined with an acceptable safety profile. Consolidation with Y-90-ibritumomab tiuxetan resulted in long-term response durations in approximately one third of the patients that received it.

Original languageEnglish
Pages (from-to)347-355
Number of pages9
JournalBritish Journal of Haematology
Volume187
Issue number3
DOIs
Publication statusPublished - Nov 2019

Keywords

  • diffuse large B-cell lymphoma
  • relapse
  • Y-90-ibritumomab tiuxetan
  • consolidation
  • PECC
  • B-CELL LYMPHOMA
  • IBRITUMOMAB TIUXETAN
  • ELDERLY-PATIENTS
  • PLUS RITUXIMAB
  • OPEN-LABEL
  • TRIAL
  • CHOP
  • CHEMOTHERAPY
  • MULTICENTER
  • COMBINATION

Fingerprint

Dive into the research topics of 'Rituximab‐ PECC induction followed by 90 Y‐ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT : results from a phase II HOVON study'. Together they form a unique fingerprint.

Cite this